Canine cognitive dysfunction gets first consensus diagnostic guide
Bottom line
Canine cognitive dysfunction syndrome gets its first diagnostic playbook
Veterinarians now have the first consensus-based guidelines for diagnosing and monitoring canine cognitive dysfunction syndrome, or CCDS, a step experts say was overdue as more dogs live long enough to develop age-related cognitive decline. The international CCDS Working Group, led by North Carolina State University neurologist Natasha Olby and published in JAVMA, defines CCDS as a chronic, progressive, age-associated neurodegenerative syndrome marked by changes across the DISHAA domains: disorientation, social interaction, sleep disruption, house soiling, learning and memory, activity changes, and anxiety. The guidance also lays out two diagnostic levels, one based on history, exams, and routine lab work, and another that adds advanced testing such as MRI and cerebrospinal fluid analysis, plus a three-stage severity framework for ongoing monitoring. (pubmed.ncbi.nlm.nih.gov)
Why it matters: For primary care teams, the biggest shift is that CCDS diagnosis starts with definitions and exclusion, not assumption. Olby and other experts have stressed that many behavior changes seen in senior dogs can also reflect pain, endocrine disease, sensory decline, intracranial disease, or other comorbidities, which means a careful history, physical, orthopedic, and neurologic exam remain central to workup. That emphasis matches recent survey data showing broad variation in how U.S. veterinarians diagnose and manage CCDS, along with uncertainty about best practices. At the same time, clinicians are seeing more cognitive decline in practice as pets live longer, making a shared framework more useful for triage, client communication, case documentation, and follow-up. (cvm.ncsu.edu)
What to watch: Expect the next phase to focus on validating practical biomarkers, refining staging tools, and building clinic-ready screening pathways for senior dogs. (akcchf.org)
Key facts
- Condition
- Canine cognitive dysfunction syndrome (CCDS)
- Guideline type
- First consensus-based diagnostic and monitoring guidelines
- Published in
- JAVMA
- Working group
- International CCDS Working Group
- Lead author
- Natasha Olby, North Carolina State University
- Definition
- Chronic, progressive, age-associated neurodegenerative syndrome
- Core signs
- DISHAA: disorientation, social interaction changes, sleep disruption, house soiling, learning and memory deficits, activity changes, and anxiety
- Diagnostic levels
- Level 1 uses history, exam, and lab work; Level 2 adds MRI and cerebrospinal fluid analysis
- Monitoring framework
- Three severity stages
Canine cognitive dysfunction syndrome is moving into a more standardized era. An international working group has published what appears to be the first consensus-based diagnostic and monitoring guidelines for CCDS, giving veterinarians a formal definition of the syndrome, practical diagnostic criteria, and a shared staging framework at a time when senior-dog cognitive decline is drawing more clinical attention. (pubmed.ncbi.nlm.nih.gov)
The push for definitions came from a familiar problem in practice: veterinarians have been trying to distinguish normal aging from neurodegenerative disease without an agreed diagnostic standard. North Carolina State University’s Natasha Olby, who led the working group, said the field needed to first define what CCDS is before it could meaningfully improve diagnosis and treatment. In a 2025 survey of U.S. veterinarians, researchers reported substantial uncertainty around diagnosis and management, concluding that clear guidelines were needed to support practitioners and patients. (cvm.ncsu.edu)
In the new JAVMA paper, the group defines CCDS as a chronic, progressive, age-associated neurodegenerative syndrome characterized by cognitive and behavioral changes that affect daily life to varying degrees. The guidance centers on the DISHAA framework, covering disorientation, altered social interactions, sleep disturbances, house soiling, learning and memory deficits, activity changes, and anxiety. The authors propose three severity stages and two diagnostic levels. Level 1 relies on a consistent history of progressive DISHAA signs, exclusion of alternate causes through physical, orthopedic, and neurologic examination plus laboratory work, and persistence of signs after relevant comorbidities are addressed. Level 2 adds advanced diagnostics, including brain MRI and cerebrospinal fluid assessment. (pubmed.ncbi.nlm.nih.gov)
That structure is meant to reflect real-world constraints. AAHA’s coverage of the guidelines noted Olby’s point that a full neurologic workup, MRI, CSF sampling, and even histopathology might be ideal in theory, but often aren’t practical because of cost, anesthesia risk, or concurrent disease in geriatric patients. Instead, the framework gives primary care teams a way to make a reasoned diagnosis while still reserving advanced testing for cases where the signalment, exam findings, or differential list point beyond straightforward CCDS. (aaha.org)
Industry and academic reaction has been broadly supportive. The AKC Canine Health Foundation called the publication the first-ever guidelines for diagnosing and monitoring CCDS and paired the announcement with plans for an online resource hub. NC State described the effort as a way to unify the clinical and research sides of canine cognitive aging. That matters because biomarker work is accelerating, but reviews published in 2026 still describe the field as early, with candidate cerebrospinal fluid and blood markers under study rather than ready for routine use. (akcchf.org)
Why it matters: For veterinary professionals, the practical value is less about a new test than about a cleaner diagnostic pathway. Senior dogs with nighttime restlessness, house soiling, altered social behavior, pacing, or anxiety often present with overlapping pain, sensory loss, endocrine disease, or intracranial pathology. The new guidance reinforces that CCDS is a diagnosis built on pattern recognition plus exclusion, which may help reduce both underdiagnosis and premature diagnosis. It also gives teams a common language for discussing progression with pet parents, standardizing rechecks, and documenting response to environmental, nutritional, behavioral, or pharmacologic interventions. (cvm.ncsu.edu)
The timing also fits broader demographic change in companion animal medicine. Recent reporting from Texas A&M highlighted that veterinarians are seeing more cognitive decline in both dogs and cats as pets live longer, while pet parents are getting better at noticing subtle behavior changes. That trend is likely to increase demand for screening conversations in senior wellness visits, especially if future work on gait changes, imaging, or fluid biomarkers produces more objective tools for earlier detection and monitoring. (dvm360.com)
What to watch: The next milestones are likely to be wider uptake of the consensus criteria in primary care, validation of staging tools and biomarkers in larger dog populations, and development of clinic-friendly screening protocols that can identify at-risk patients before impairment becomes severe. (akcchf.org)